Terry Mahn, US Technical Advisor for CISPR/B Senior Principal, Fish & Richardson
Medical Device RegulationsThis Company’s False Compliance with CISPR 11 Resulted in a $12 Million FCA FineThis Company’s False Compliance with CISPR 11 Resulted in a $12 Million FCA Fine
Take it from Advanced Bionics. If you’re going to use CISPR 11 to support findings in pre-market applications, it better be correct.
Sign up for the QMED & MD+DI Daily newsletter.